CRISPR Insider Kulkarni Reports Ownership Change
| Field | Detail |
|---|---|
| Company | Kulkarni Samarth |
| Form Type | 4 |
| Filed Date | Mar 24, 2026 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: insider-transaction, form-4, ownership-change, disclosure
TL;DR
**CRISPR insider Kulkarni just filed a Form 4, signaling a change in his stock ownership.**
AI Summary
Samarth Kulkarni, an insider at CRISPR Therapeutics AG, filed a Form 4 on March 24, 2026, indicating a change in his beneficial ownership of the company's securities as of March 20, 2026. While the filing details the reporting of ownership changes, it doesn't specify the nature of the transaction (buy or sell) or the number of shares involved. This matters to investors because insider transactions can signal management's confidence (or lack thereof) in the company's future prospects, potentially influencing stock price.
Why It Matters
Insider transaction filings provide transparency into how company executives are managing their holdings, which can be a strong indicator of their belief in the company's future performance.
Risk Assessment
Risk Level: low — This filing is purely a disclosure of a change in beneficial ownership, not an inherently risky event itself.
Analyst Insight
Smart investors should look for the full Form 4 document to understand the specific nature of the transaction (buy/sell) and the number of shares involved, as this detail is crucial for interpreting the insider's sentiment.
Key Players & Entities
- Samarth Kulkarni (person) — Reporting person, an insider at CRISPR Therapeutics AG
- CRISPR Therapeutics AG (company) — The issuer of the securities
- March 24, 2026 (date) — Filing date of the Form 4
- March 20, 2026 (date) — Period of report date for the transaction
FAQ
Who is Samarth Kulkarni in relation to CRISPR Therapeutics AG?
Samarth Kulkarni is the 'Reporting' person, indicating he is an insider (e.g., officer, director, or 10% owner) of CRISPR Therapeutics AG, the 'Issuer'.
What is the purpose of a Form 4 filing?
A Form 4 is a 'Statement of changes in beneficial ownership of securities' filed with the SEC to report transactions by company insiders in their company's stock.
When was this Form 4 filed and what is the period of report?
This Form 4 was filed on March 24, 2026, and the 'Period of Report' for the transaction it covers is March 20, 2026.
What is the CIK for CRISPR Therapeutics AG?
The CIK (Central Index Key) for CRISPR Therapeutics AG is 0001674416.
Does this filing indicate whether Samarth Kulkarni bought or sold shares?
No, this filing only states that it is a 'Statement of changes in beneficial ownership of securities' and does not provide details within the provided text about whether the change was a purchase or a sale, or the number of shares involved.
Filing Stats: 909 words · 4 min read · ~3 pages · Grade level 7.6 · Accepted 2026-03-24 17:37:54
Filing Documents
- ownership.html (4)
- ownership.xml (4) — 12KB
- 0001193125-26-122272.txt ( ) — 14KB
From the Filing
SEC FORM 4 SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. 1. Name and Address of Reporting Person * Kulkarni Samarth (Last) (First) (Middle) C/O CRISPR THERAPEUTICS 105 WEST FIRST STREET (Street) BOSTON MASSACHUSETTS 02127 (City) (State) (Zip) UNITED STATES (Country) 2. Issuer Name and Ticker or Trading Symbol CRISPR Therapeutics AG [ CRSP ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner X Officer (give title below) Other (specify below) Chief Executive Officer 2a. Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) 03/20/2026 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 4. If Amendment, Date of Original Filed (Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Shares 03/20/2026 M (1) 19,687 A (2) 265,521 D Common Shares 03/23/2026 S 10,020 (3) D $ 46.78 255,501 D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 46.24 03/20/2026 A (1) 114,249 (4) 03/20/2036 Common Shares 114,249 $ 0.00 114,249 D Restricted Stock Units (5) 03/20/2026 A (1) 81,875 (5) (5) Common Shares 81,875 $ 0.00 81,875 D Restricted Stock Units (2) 03/20/2026 M (1) 19,687 (6) (6) Common Shares 19,687 (2) 39,375 D Explanation of Responses: 1. These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. 2. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. 3. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. 4. This option was granted on March 20, 2026 with respect to 114,249 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 20, 2026. 5. This restricted stock unit award was granted on March 20, 2026 with respect to 81,875 Common Shares, with (i) one quarter of the shares vesting on March 20, 2027 , (ii) one quarter of the shares vesting on March 20, 2028, (iii) one quarter of the shares vesting on March 20, 2029, and (iv) one quarter of the shares vesting on March 20, 2030. 6. This restricted stock unit award was granted on March 20, 2024 with respect to 78,750 Common Shares, with (i) one quarter of the shares vesting on March 20, 2025, (ii) one quarter of the shares vesting on March 20, 2026, (iii) one quarter of the shares vesting on March 20, 2027, and (iv) one quarter of the shares vesting on March 20, 2028. Elizabeth Ryland Waldinger, attorney-in-fact 03/24/2026 ** Signature of Repor